pharma · Asthma · Respiratory Syncytial Virus Infections
GSK Glaxo Smith
GlaxoSmithKline
GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
- Employees
- 30
- Programs
- 205
- Drugs
- 194
- Patents
- 0
222090
Phase 3 · small molecule · Respiratory Syncytial Virus Infections
222090 for Respiratory Syncytial Virus Infections is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Internal code 222090
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Respiratory Syncytial Virus Infections
- Status
- active
- Trials
- 1